Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

Interpace Biosciences projects Q3 2026 revenue up 11–14% sequentially to $10.1–$10.4 million.

What the company is saying

Interpace Biosciences (OTCID: IDXG) is communicating that its preliminary, unaudited revenue for the third quarter of 2026 is expected to range from $10.1 million to $10.4 million. The company frames this as sequential growth of 11% to 14% over Q2 2026 revenue of $9.1 million and a year-over-year increase of 15% to 18% over Q3 2025 revenue of $8.8 million. The announcement repeatedly emphasizes that these figures are preliminary, unaudited, and subject to change following quarter-end closing procedures and review by the independent registered public accounting firm. The company does not provide any explanation for the revenue growth or details on profitability, expenses, or cash flow. The tone is measured, with explicit caveats that actual results may differ materially from the estimates. Interpace also highlights its commercialized thyroid diagnostic tests, ThyGeNEXT and ThyraMIR v2, as part of its core business narrative.

What the data suggests

The disclosed figures show a clear upward trajectory in revenue, with Q3 2026 preliminary revenue estimated at $10.1 million to $10.4 million, up from $9.1 million in Q2 2026 and $8.8 million in Q3 2025. This represents sequential growth of 11% to 14% and year-over-year growth of 15% to 18%. The company provides only revenue data, without any information on margins, profitability, or cash flow, limiting the ability to assess the quality of growth. The estimates are unaudited and explicitly flagged as subject to adjustment, so there is a risk that final results could differ. No operational or market drivers for the revenue increase are disclosed. The data is transparent for revenue but incomplete for broader financial analysis.

Analysis

The announcement presents preliminary, unaudited revenue growth for Q3 2026, showing both sequential and year-over-year increases. The tone is positive but proportionate to the evidence, as the company clearly states the figures are estimates and subject to change. There is no exaggeration of realised progress; the language is careful to note the preliminary and unaudited nature of the data, and there are explicit caveats that actual results may differ. No profitability, cash flow, or margin data is disclosed, so the signal cannot be stronger than weak_positive. There is no mention of large capital outlays or long-dated, uncertain returns. The majority of key claims (revenue estimates and growth rates) are forward-looking but pertain to the just-ended quarter, so the execution distance is immediate.

Risk flags

• ●The revenue figures are preliminary and unaudited, meaning they could change materially after quarter-end review and audit. This introduces uncertainty for investors relying on these numbers.
• ●No profitability, margin, or cash flow data is provided, so it is unclear whether revenue growth translates into improved earnings or financial health. Revenue growth alone does not guarantee better bottom-line results.
• ●The company does not disclose any drivers or explanations for the revenue increase, making it difficult to assess whether the growth is sustainable or driven by one-time factors.

Bottom line

Interpace Biosciences is signaling strong revenue growth for Q3 2026, with preliminary unaudited revenue expected to rise to $10.1–$10.4 million, up 11–14% sequentially and 15–18% year-over-year. The announcement is limited to top-line figures and does not address profitability, margins, or the reasons behind the growth, leaving key questions about the quality and sustainability of the improvement. The figures are subject to audit and could change, so investors should treat them as indicative rather than definitive. The most important takeaway is that revenue momentum appears positive, but a full assessment will require the complete financial results, including earnings and cash flow, when released. Watch for the audited Q3 2026 report to confirm whether this revenue growth translates into broader financial strength.

Announcement summary

(OTCID: IDXG) Interpace Biosciences, Inc. announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million. This expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026. The expected revenue range also represents an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025. The estimated revenue figures are preliminary and unaudited, based on information currently available to management, and remain subject to completion of the Company’s quarter-end closing procedures and review by the Company’s independent registered public accounting firm. Actual results may differ, including materially, from the range presented. The Company expects to report complete financial results for the third quarter of 2026 at a later date. Interpace Biosciences commercializes specialized molecular diagnostic tests and related services, including ThyGeNEXT® and ThyraMIR® v2, which are used together to support the evaluation of indeterminate thyroid nodules. The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this free writing prospectus communication relates. The preliminary, unaudited financial information in this release has not been reviewed by the Company’s independent registered public accounting firm and is subject to change as the Company completes its quarter-end closing and review procedures. The Company’s expected revenues for the third quarter of 2026 may not be indicative of the Company’s net income for such period or for full year results.

Disagree with this article?